
Three years ago on Translating Aging, Matthew "Oki" O'Connor promised he'd come back when UDP-003 had been in humans. This week, he makes good. The CEO of Scientific Affairs at @Cyclarity returns with Phase 1 data on a cyclodextrin designed to do something no approved cardiovascular drug has ever done: physically remove an accumulated toxin — 7-ketocholesterol — from arterial plaque. Seventy-two volunteers, no serious adverse events, dose-dependent clearance confirmed. Phase 2 is next, with plaque imaging as the endpoint. Translating Aging is produced by @bioagelabs , a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. 🎧 Apple: podcasts.apple.com/us/podcas… Spotify: open.spotify.com/episode/7eo…












